Literature DB >> 25455993

Diagnostic significance of cell kinetic parameters in World Health Organization type A and B3 thymomas and thymic carcinomas.

Anja C Roden1, Eunhee S Yi2, Sarah M Jenkins3, Janis L Donovan2, Stephen D Cassivi4, Yolanda I Garces5, Randolph S Marks6, Marie-Christine Aubry2.   

Abstract

The prognostic importance of histologic classifications of thymic epithelial neoplasms is controversial. Evidence suggests that difficulties in reproducibility affect prognostic studies. Two thoracic pathologists independently classified 80 cases of type A or B3 thymoma and thymic carcinoma according to World Health Organization (WHO) classification. Ki-67 labeling index (LI) was used to identify cutoff points between WHO types. Recursive partitioning (Rpart) and ad hoc methods separated the data points. The pathologists agreed on type A (n = 31), type B3 (n = 21), and thymic carcinoma (n = 14). Ki-67 LI differed between types A and B3 (P < .001) and between thymic carcinoma and type A (P < .001) or type B3 (P = .001). Mitotic activity differed between thymic carcinoma and type A (P < .001) or type B3 (P < .001). Rpart revealed Ki-67 LI greater than 14.0% only in thymic carcinoma; cases with Ki-67 LI less than 5.1% did not represent thymic carcinoma. Ad hoc analysis showed Ki-67 LI greater than or equal to 13.5% represents thymic carcinoma; only type A had Ki-67 LI less than 2%. The pathologists disagreed on histologic type in 14 cases. In 11 of 14 cases with available Ki-67, the Rpart method predicted the WHO type; in 7 of 14 cases, the ad hoc method predicted the WHO type. In conclusion, Ki-67 LI is helpful in differentiating thymic epithelial neoplasms, with Ki-67 LI less than 2% and greater than or equal to 13.5% distinguishing type A thymoma and thymic carcinoma, respectively.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bcl-2; Ki-67 labeling index; Mitoses; Thymic carcinoma; Thymoma

Mesh:

Substances:

Year:  2014        PMID: 25455993     DOI: 10.1016/j.humpath.2014.10.001

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

Authors:  Priska Leisibach; Didier Schneiter; Alex Soltermann; Yoshi Yamada; Walter Weder; Wolfgang Jungraithmayr
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 2.  Common and rare carcinomas of the thymus.

Authors:  Anja C Roden; Malgorzata Szolkowska
Journal:  Virchows Arch       Date:  2021-01-03       Impact factor: 4.064

3.  Minimally invasive thymectomy: the Mayo Clinic experience.

Authors:  Phillip G Rowse; Anja C Roden; Frank M Corl; Mark S Allen; Stephen D Cassivi; Francis C Nichols; K Robert Shen; Dennis A Wigle; Shanda H Blackmon
Journal:  Ann Cardiothorac Surg       Date:  2015-11

4.  CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma.

Authors:  Mounika Angirekula; Sindy Y Chang; Sarah M Jenkins; Patricia T Greipp; William R Sukov; Randolph S Marks; Kenneth R Olivier; Stephen D Cassivi; Anja C Roden
Journal:  Cancers (Basel)       Date:  2022-05-05       Impact factor: 6.575

5.  A case of atypical type A thymoma variant.

Authors:  Masaki Hashimoto; Shigeki Shimizu; Teruhisa Takuwa; Yoshitane Tsukamoto; Tohru Tsujimura; Seiki Hasegawa
Journal:  Surg Case Rep       Date:  2016-10-21

6.  High CTLA-4 expression correlates with poor prognosis in thymoma patients.

Authors:  Giorgio Santoni; Consuelo Amantini; Maria Beatrice Morelli; Daniele Tomassoni; Matteo Santoni; Oliviero Marinelli; Massimo Nabissi; Claudio Cardinali; Vittorio Paolucci; Mariangela Torniai; Silvia Rinaldi; Francesca Morgese; Giovanni Bernardini; Rossana Berardi
Journal:  Oncotarget       Date:  2018-03-30

7.  Relationship of possible biomarkers with malignancy of thymic tumors: a meta-analysis.

Authors:  Huilan Zeng; Weilin Yang; Bo Xu; Jianyong Zou; Chunhua Su; Beilong Zhong; Haoshuai Zhu; Zhenguang Chen
Journal:  BMC Cancer       Date:  2020-09-29       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.